Table 2.
Baseline characteristics of the 54 patients included in this study
| Patients characteristics | |
|---|---|
| Age (mean ± SD) | 56.04 ± 16.54 |
| Gender (F/M) | 20/34 |
| BMI (mean ± SD) | 29.1 ± 8.43 |
| Charlson comorbidity index (mean ± SD) | 3.31 ± 2.39 |
| SAPS II at admission (mean ± SD) | 43.04 ± 17.49 |
| SOFA at admission (mean ± SD) | 8.36 ± 4.02 |
| Timing of sample collection since ICU admission (mean ± SD) | 0.98 ± 1.54 |
|
Herpesviruses DNA (BAL) % (yes/no) |
31.5 17/37 |
|
Influenza virus RNA (BAL) % (yes/no) |
35.2 19/35 |
| Oseltamivir (yes/no) | 19/35 |
| Zanamivir (yes/no) | 6/48 |
| Aciclovir/ganciclovir(yes/no) | 6/48 |
| Steroid drugs (yes/no) | 7/47 |
| SAPS II at discharge (mean ± SD) | 20.85 ± 12.71 |
| Ventilation LOS, days (mean ± SD) | 18.48 ± 17.67 |
| ICU LOS, days (mean ± SD) | 22.19 ± 20.98 |
| Post-ICU LOS, days (mean ± SD) | 10.57 ± 12.73 |
|
ICU mortality % (yes/no) |
31.5 17/37 |
|
H mortality % (yes/no) |
5.7 2/35 |
BMI body mass index; LOS length of stay; H hospital